Boehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025

Boehringer Ingelheim 2024 (PRNewsfoto/Boehringer Ingelheim Pharmaceuticals, Inc.) (PRNewsfoto/Boehringer Ingelheim)

  • Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancers
  • Patient-reported outcomes from the Beamion LUNG-1 study in previously treated patients with HER2 (ERRB2)-mutant advanced non-small cell lung cancer (NSCLC) reported physical function and disease-related symptom improvement while being treated with zongertinib1
  • New data from a study of T-cell engager, obrixtamig, show encouraging findings in the treatment of extrapulmonary neuroendocrine carcinomas in patients with high DLL3 expression2

RIDGEFIELD, Conn., May 22, 2025 /PRNewswire/ --Boehringer Ingelheim will present the latest data in its robust oncology pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including patient-reported outcomes (PRO) from the Beamion LUNG-1 study evaluating zongertinib as an orally administered targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). In addition, new data evaluating the efficacy and safety of obrixtamig for the treatment of extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression will be featured in an oral session. 

Recommended for you